Initial targeted sequencing of the four patients revealed that all patients harbored MDM2 amplification, therefore, we hypothesized that MDM2 amplification may induce primary resistance to EGFR-TKIs and result in a poor prognosis of NSCLC patients harboring sensitive EGFR mutations. The gene discussed is MDM2; the disease is non-small cell lung carcinoma.